Management of Chemical Gastritis Without H. pylori
For antral gastric mucosa with mild chronic gastritis showing foveolar hyperplasia suggestive of chemical gastritis and no H. pylori, the primary management is identifying and eliminating the causative agent (NSAIDs, bile reflux), with no routine endoscopic surveillance required unless atrophy or intestinal metaplasia develops.
Immediate Management Steps
1. Identify and Remove the Causative Agent
Chemical gastritis (reactive gastropathy) with foveolar hyperplasia typically results from:
- NSAIDs or aspirin - discontinue or switch to COX-2 selective agents if necessary
- Bile reflux - consider prokinetic agents or surgical evaluation if severe
- Alcohol - cessation counseling
The foveolar hyperplasia pattern you describe is the hallmark histologic feature of chemical injury 1. This represents a reactive change rather than a precancerous condition.
2. Confirm H. pylori Negativity
Since histology showed no organisms, this is likely adequate. However, if the patient has been on proton pump inhibitors (PPIs) recently, be aware that PPIs can suppress H. pylori to undetectable levels and create a chronic inactive gastritis pattern 2. Consider:
- Urea breath test or stool antigen if clinical suspicion remains high
- Stopping PPIs for 2 weeks before retesting if initially on these medications
3. Symptomatic Treatment
- PPIs or H2-blockers for symptom control if needed
- Sucralfate has mucosal protective properties and may help histologic improvement 3
- Address any micronutrient deficiencies if present (though less common without atrophy)
Surveillance Strategy
No routine endoscopic surveillance is indicated for isolated chemical gastritis without atrophy or intestinal metaplasia. The key distinction here is critical:
When Surveillance IS NOT Needed (Your Case):
- Mild chronic gastritis without activity
- Foveolar hyperplasia (reactive change)
- No atrophy mentioned
- No intestinal metaplasia mentioned
- No H. pylori
When Surveillance WOULD Be Needed:
According to the 2021 AGA guidelines on atrophic gastritis 4 and 2025 AGA screening guidelines 5, surveillance is reserved for:
- Atrophic gastritis (AG) - particularly if severe
- Gastric intestinal metaplasia (GIM) - every 3-5 years depending on extent
- Dysplasia - much more frequent intervals (6-12 months for LGD, 3 months for HGD)
Follow-Up Plan
Short-Term (4-8 weeks):
- Reassess symptoms after removing causative agent
- Confirm medication changes implemented
- Consider repeat testing for H. pylori if initial testing was potentially compromised by PPI use
Long-Term:
- No routine repeat endoscopy unless new symptoms develop
- Clinical follow-up as needed for symptom management
- If causative agent cannot be eliminated (e.g., requires chronic NSAIDs), consider chronic PPI therapy for gastroprotection
Important Caveats
Watch for these pitfalls:
Don't confuse chemical gastritis with atrophic gastritis - they have completely different cancer risks and surveillance needs. Your pathology report does not mention atrophy, which is reassuring 4.
Foveolar hyperplasia at the cardia can be associated with junctional inflammation rather than true chemical injury 1, but antral location makes bile/NSAID etiology more likely.
If the patient develops iron or B12 deficiency later, this would prompt reconsideration of atrophic gastritis (particularly autoimmune) and warrant repeat endoscopy 4.
Chronic inactive gastritis can mask H. pylori if the patient recently received PPIs or partial eradication therapy 2. The organisms may be present in coccoid forms that are harder to detect.
Documentation for Patient
Explain that:
- This is a reactive change, not a precancerous condition
- The most important treatment is stopping the irritating substance (NSAIDs, alcohol, etc.)
- No cancer risk from this finding alone
- Repeat endoscopy is not routinely needed unless new symptoms develop
- If atrophy or intestinal metaplasia were present (which they are not), surveillance would be different